Please assess the completion status of the following clinical trial:

Trial Title: RATe Control in Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent or permanent atrial fibrillation with ventricular rate \> 80/min at rest and/or \> 100/min average at daytime.~* Male or female, age \> 18.~Exclusion Criteria:~* Hypersensitivity or contraindication to metoprolol, verapamil, diltiazem or carvedilol.~* Coronary heart disease or heart failure~* Systolic blood pressure \< 100 mmHg~* AV-conduction disturbance~* Severe hepatic or renal dysfunction~* Thyrotoxicosis~* Ongoing treatment with Digitalis~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoprolol (Type: ACTIVE_COMPARATOR): Treatment with Metoprolol 100 mg x 1 for three weeks
- Diltiazem (Type: ACTIVE_COMPARATOR): Treatment with Diltiazem 360 mg x 1 for three weeks
- Verapamil (Type: ACTIVE_COMPARATOR): Treatment with Verapamil 240 mg x 1 for three weeks
- Carvedilol (Type: ACTIVE_COMPARATOR): Treatment with Carvedilol 25 mg x 1 for three weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).